Therapeutic opportunities for targeted liposomal drug delivery
References (100)
- et al.
Antitumor efficacy of taxane liposomes on a human ovarian tumour xenograft in nude athymic mice
J. Pharm. Sci.
(1995) - et al.
Pharmacokinetics of long circulating liposomes
Adv. Drug Del. Rev.
(1995) - et al.
Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue
Biochim. Biophys. Acta
(1992) - et al.
Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro
Hepatology
(1995) - et al.
Folate-mediated tumour cell targeting of liposome-entrapped doxorubicin in vitro
Biochim. Biophys. Acta
(1995) - et al.
Targeting of anti-Thy 1.1 monoclonal antibody conjugated liposomes in Thy 1.1 mice after intravenous administration
Biochim. Biophys. Acta
(1987) - et al.
Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes
Biochim. Biophys. Acta
(1979) - et al.
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient
Biochim. Biophys. Acta
(1986) - et al.
Optimization of the retention properties of vincristine in liposomal systems
Biochim. Biophys. Acta
(1993) - et al.
Liposomes for the sustained drug release in vivo
Biochim. Biophys. Acta
(1990)
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes
FEBS Lett.
Influence of surface hydrophobicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly (ethylene glycol)-coated vesicles
Biochim. Biophys. Acta
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo
Biochim. Biophys. Acta
The use of glycolipids and hydrophillic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system
Adv. Drug Del. Rev.
Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles
Biochim. Biophys. Acta
Pharmacokinetics of Stealth versus conventional liposomes: effect of dose
Biochim. Biophys. Acta
Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures
Biochim. Biophys. Acta
Influence of the steric barrier of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo
FEBS Lett.
Activity of amphipathic poly(ethyleneglycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target
Biochim. Biophys. Acta
Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting
J. Biol. Chem.
A non-covalent method of attaching antibodies to liposomes
Biochim. Biophys. Acta
Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N-hydorosulfosuccinimide
FEBS Lett.
Highly efficient immunoliposomes prepared with a method which is compatible with various lipid compositions
Biochem. Biophys. Res. Commun.
Optimized procedures for the coupling of proteins to liposomes
J. Immunol. Meth.
Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine
FEBS Lett.
Preparation and applications of polyethylene glyol-polystyrene graft resin supports of solid phase peptide synthesis
Reactive Polymers
A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells
Biochim. Biophys. Acta
Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times
Biochim. Biophys. Acta
Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol)
Biochim. Biophys. Acta
Adhesion molecules: a new target for immunoliposome-mediated drug delivery
FEBS Lett.
Design of immunoliposomes directed against human ovarian carcinoma
Biochim. Biophys. Acta
Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies
Biochim. Biophys. Acta
Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay
Biochim. Biophys. Acta
Conjugation of apolipoprotein B with liposomes and targeting to cells in culture
Biochim. Biophys. Acta
Immunogenicity of immunoliposomes
Immunol. Lett.
Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumour model
Cancer Res.
Novel taxol formulations: taxolcontaining liposomes
Monographs Natl. Cancer Inst.
Embryotoxicity of free and liposome encapsulated taxol in the chick
Pharmacology
Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use
J. Microencapsulation
In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes
Cancer Chemother. Pharmacol.
Inhibition of tumour cell growth in vitro and in vivo by 1-β-D-arabinofuranosylcytosine entrapped within phospholipid vesicles
Cancer Res.
Multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy
Cancer Treat. Rep.
Therapy of central nervous system leukemia in mice by liposome-entrapped 1-beta-D-arabinofuranosylcytosine
Cancer Res.
Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine
Cancer Res.
Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times
J. Natl. Cancer Inst.
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
Cancer Res.
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies
J. Clin. Oncol.
Efficacy and safety of StealthR liposomal doxorubicin in AIDS-related Kaposi's sarcoma
Br. J. Cancer
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumour localization, and safety inpatients with AIDS-related Kaposi's sarcoma
J. Clin. Pharmacol.
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes)
Cancer Res.
Cited by (123)
Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
2021, Journal of Controlled ReleaseFolic acid mediated endocytosis enhanced by modified multi stimuli nanocontainers for cancer targeting and treatment: Synthesis, characterization, in-vitro and in-vivo evaluation of therapeutic efficacy
2020, Journal of Drug Delivery Science and TechnologySynthesis, characterization and evaluation of multi sensitive nanocarriers by using the layer by layer method
2019, Journal of Drug Delivery Science and TechnologyCitation Excerpt :The size of these particular drug delivery systems plays a crucial role since permits to exploit the enhanced penetration and retention (EPR) effect [4], where the nanospheres extravasate into tumour tissue through discontinuous blood vessels and remain in that place due to impaired lymphatic drainage [5–9]. Additionally, introducing tumour targeting agents into these systems’ surface can also enhance their accumulation in cancer cells via active targeting [8,10–16]. This functionalization can strengthen the biodistribution of the carried drugs and invigorate the therapeutic index as well while minimizing side effects.
Nanoparticulate drug delivery systems for the oral administration of macromolecular drugs
2019, Nanoparticles in PharmacotherapyMolecular platforms for targeted drug delivery
2019, International Review of Cell and Molecular BiologyCitation Excerpt :Overall, this alternative system for the targeted controlled intracellular delivery of model macromolecules and small molecules loaded in the liposome-based on local microenvironmental activation showed promising results that now require in vivo validation. Subsequent studies investigated ligand-targeted liposomes as a strategy to increase interactions between liposomes and target cells and to enhance drug delivery (Allen and Moase, 1996). While non-targeted liposomal drug formulations display consistent therapeutic improvements in term of systemic toxicity when compared to free drug treatment (Safra et al., 2000), selective targeting of cells via ligand-directed liposomes will improve tumor drug accumulation and uptake, resulting in elevated anti-tumor effects (Park et al., 2002).